Helpful Information from Industry

The information contained on this page is provided by the respective companies noted. It does not necessarily reflect the Society’s viewpoint and may redirect the user to a third-party site. ASE has posted this content on ContrastZone as a convenient way to access multiple pieces of information in one place, in alignment with our Society’s goal to provide resources and education to enhance the access to and quality in cardiovascular ultrasound.

Bracco Diagnostics

January 2017: The FDA removes the contraindication for use of Bracco Diagnostics Inc.’s LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use, in patients with cardiac shunts

March 2016: LUMASON is now FDA approved for use in ultrasonography of the liver

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading companies in the diagnostic imaging business, announced today that LUMASON is now approved for use in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients.

Please read the press release and prescribing information for more information.

Lumason Formulary Kit: includes Lumason Product Monograph, Safety Data Sheet, FDA Approval Letter, and Prescribing Information

Lumason Brochure: overview of product

2017 LUMASON^® Reimbursement Guide

November 2015: Lumason® approved for reimbursement by CMS
To learn more about how to code Bracco’s new ultrasound contrast agent, visit here and read the press release here.